| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: ACLA |
| Security Type |
Common Stock |
| Lead Underwriter |
Deutsche Banc Alex Brown Warburg Dillon Read Inc |
| Days In Registration |
57 |
| Date Filed |
24-Jan-2000 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2008) |
| Industry |
Manufacturing |
| Business Description |
Biotechnology company focusing on microfluidics |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
- |
| President and CEO |
Joseph M. Limber |
| Number of Employees |
60 |
|
| Original Filing Information |
| US |
| Shares Filed |
9.0M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
9.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
1350.0K |
| File Amount |
$126.0M |
| File Price Range |
$15.00 - $13.00 |
| File Mid Price |
$14.00 |
Current Filing Information
(Amended 17-Mar-2000) |
|
US |
|
Shares Filed |
9.0M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
9.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$153.0M |
| · % Change from Original |
21.43 |
| File Price Range |
$18.00 - $16.00 |
| File Mid Price |
$17.00 |
|
